ARHGAP26 and ovarian cancer: In the present study, ovarian cancer cells treated with DDK1, an antagonist of the β-catenin pathway, demonstrated decreased cell migration and invasion induced by ARHGAP26 silencing, indicating that ARHGAP26 regulates ovarian cancer cell invasion and migration by regulating VEGF, MMP2, and MMP7 expression through the β-catenin signaling pathway.